Life Sciences

BiomX raises $32M series B to bring first two therapies to clinic
21 February 2019

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...

Read more
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800
19 February 2019

Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800

Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

Read more
MycoTechnology Raises $30 Million in Series C Financing Round with Investments from the Biggest Names in Food
30 January 2019

MycoTechnology Raises $30 Million in Series C Financing Round with Investments from the Biggest Names in Food

The $30 million in new investment will fuel expansion and accelerate R&D project execution. This funding round opens up an opportunity to explore different ways to meet...

Read more
Novartis reimagines neurosciences by developing smart templates that measure progression in MS patients, in collaboration with FeetMe and the Vithas Nisa Foundation
20 December 2018

Novartis reimagines neurosciences by developing smart templates that measure progression in MS patients, in collaboration with FeetMe and the Vithas Nisa Foundation

Specialized in smart medical devices, FeetMe focused on the development of portable insoles that measure progression in patients with multiple sclerosis (MS).

Read the press release
Israeli microbiome co BiomX teams with Johnson & Johnson
13 December 2018

Israeli microbiome co BiomX teams with Johnson & Johnson

Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...

Read more
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26 October 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies

Read the press release